| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Nuclear Medicine and Brain Pathophysiology
Department of Surgery, Kyoto University Faculty of Medicine, Kyoto, Japan
Correspondence: For correspondence or reprints contact: Tetsuro Inokuma, MD, Department of Nuclear Medicine, Kyoto University Faculty of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606 Japan.
ABSTRACT
This study compares the diagnostic value of 18F-FDG PET imaging and 201Tl-SPECT imaging in patients with pancreatic cancer. Methods: Twenty-five patients with histologically-proven pancreatic cancer were studied. Following PET transmission scanning, 3 mCi of 201Tl were administered after patients had fasted overnight. Thallium-201-SPECT images were obtained 15 min later. Immediately after 201Tl-SPECT imaging, 4 mCi of FDG were administered and PET images were obtained 60 min later. The PET and SPECT images were compared qualitatively and quantitatively. For quantitative analysis, 10 x 10 mm2 regions of interest (ROIs) were selected in areas of the tumor showing the highest tracer accumulation and in the normal pancreas. The tumor to nontumor activity ratio (T/N ratio) was calculated. Results: Although both techniques delineated focal lesions with an increase in tracer accumulation in 16 patients, PET identified eight additional patients in whom 201Tl-SPECT images did not visualize any lesion. Thus, FDG-PET provided significantly higher sensitivity (96%) than 201Tl-SPECT (64%). Among the patients showing increased tracer accumulation, the T/N ratio was significantly higher with FDG-PET (3.24 ± 1.27) than with 201Tl-SPECT (1.77 ± 0.37) (p < 0.0001). Conclusion: We conclude that FDG-PET has a larger clinical value for noninvasive detection of pancreatic cancer than 201Tl-SPECT. If a PET camera is available, FDG-PET is considered to be the method of choice for the evaluation of patients with suspected pancreatic cancer.
Key Words: PET • pancreatic cancer • thallium-201 • fluorine-18-fluorodeoxyglucose
This article has been cited by other articles:
|
|
 |
|
  I. Ilias and K. Pacak Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 479 - 491. [Full Text] [PDF]
|
|
|
|
|
|
I. Ilias, J. Yu, J. A. Carrasquillo, C. C. Chen, G. Eisenhofer, M. Whatley, B. McElroy, and K. Pacak Superiority of 6-[18F]-Fluorodopamine Positron Emission Tomography Versus [131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4083 - 4087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B B Chin and R L Wahl 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies Gut, June 1, 2003; 52(90004): iv23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ishimori, T. Saga, M. Mamede, H. Kobayashi, T. Higashi, Y. Nakamoto, N. Sato, and J. Konishi Increased 18F-FDG Uptake in a Model of Inflammation: Concanavalin A-Mediated Lymphocyte Activation J. Nucl. Med., May 1, 2002; 43(5): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Seitz, M. Wagner, A. T. Vogg, G. Glatting, B. Neumaier, F. R. Greten, R. M. Schmid, and S. N. Reske In Vivo Evaluation of 5-[18F]Fluoro-2'-deoxyuridine as Tracer for Positron Emission Tomography in a Murine Pancreatic Cancer Model Cancer Res., May 1, 2001; 61(10): 3853 - 3857. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
